{"url_path":"/sec/aura/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1501796/0001193125-26-343408-index.html","accession_number":"0001193125-26-343408","cik":"0001501796","ticker":"AURA","issuer_name":"Aura Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1501796/0001193125-26-343408-index.html","primary_entity_key":"0001501796","primary_entity_name":"Aura Biosciences, Inc."},"word_count":129,"has_tables":true,"body_markdown":"## Item 2.02 Results of Operations and Financial Condition.\n\nOn August 11, 2026, (the “Effective Date”), Aura Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\nThe information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing."}